AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02670876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-bullying intervention
Description: The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem
Study NCT03136939 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00576771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV
Description: Pressure Support Ventilation
Study NCT00576771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Neurally Adjusted Ventilatory Assist
Study NCT00576771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient-controlled
Description: assisted controlled MV through a button
Study NCT01468649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR Imaging with FLARE and Mini-FLARE Imaging System
Description: A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
Study NCT02811744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-acetate
Description: Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
Study NCT02811744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 11C-acetate
Description: Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
Study NCT04610099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Banded Sleeve Gastrectomy
Description: banded sleeve gastrectomy
Study NCT04610099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SG
Description: Standard SG
Study NCT03751293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
Study NCT03642184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Dosage adjustment based on glucose targets . Once daily
Study NCT03642184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Dosage adjustment based on glucose targets. Once daily
Study NCT01975103 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Topcon Endpoint Management
Study NCT01975103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topcon Endpoint Management
Study NCT02669693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: bread without olives
Study NCT02669693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bread with olives
Study NCT00492219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard M fixed-bearing or Oxford mobile-bearing prostheses
Description: Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
Study NCT00492219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
Study NCT00128687 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: risk reduction
Description: Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
Study NCT00128687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: risk reduction
Description: Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
Study NCT05723887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-Based Intervention Program
Description: Attachment-Based Intervention Program
Study NCT02091440 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implant of the HW005 Ventricular Assist System.
Description: The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
Study NCT01771783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI-ARB-RI
Study NCT01771783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB-RI-ACEI
Study NCT01771783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RI-ACEI-ARB
Study NCT03981445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
Study NCT01804816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standardized acupuncture administration for 10 sessions.
Study NCT01804816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No intervention during this period. This was a control period. Each subject acted as their own control.
Study NCT01152541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin/Dextran
Description: Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
Study NCT01152541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic Riboflavin
Description: Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
Study NCT03701009 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CBD stone removal via lithotripsy
Description: Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
Study NCT03701009 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline 50ml
Description: If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
Study NCT03701009 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Saline +50ml
Description: If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
Study NCT02863848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OraftiR inulin-type fructans
Study NCT02863848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin
Study NCT02969018 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03428373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10mg daily
Study NCT03428373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: ASA 81mg
Study NCT00868387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy-restricted, CHO-restricted diet
Description: carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
Study NCT00868387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy-restricted, CHO-rich diet
Description: carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
Study NCT00777543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ferulic acid
Description: Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
Study NCT00777543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ferulic acid
Description: Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
Study NCT00777543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treated bran bread
Description: This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
Study NCT01763177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen mask 40% 8 LPM for 30 minutes
Study NCT03622801 — intervention group
Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
Study NCT01494532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole/L-dopa
Description: Ropinirole as adjunctive therapy with L-dopa
Study NCT01494532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/L-dopa
Description: Placebo as adjunctive therapy with L-dopa
Study NCT04513587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based weight loss model
Description: Methods of cognitive behavioral psychotherapy
Study NCT04513587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study NCT04839276 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat
Description: Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
Study NCT04839276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Laryngoplasty with Autologous Fat
Description: Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
Study NCT04975035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolodine
Description: Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
Study NCT02659358 — intervention group
Intervention type: DEVICE
Intervention: Fitbit Charge HR®
Description: A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
Study NCT03158467 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
Study NCT04365153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab Injection 600mg
Description: Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
Study NCT04365153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab Injection 300mg
Description: Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
Study NCT04365153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 250 mL of 5% dextrose infused IV over 2 hours
Study NCT04167267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
Study NCT04167267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study NCT01724372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant
Study NCT01724372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic
Study NCT02544672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoelectric Elbow-Wrist-Hand orthosis
Description: An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
Study NCT03675269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBOT
Description: Standard practice
Study NCT03675269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound care
Description: Standard wound care
Study NCT03675269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: Standard wound care
Study NCT00112957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rV-NY-ESO-1 vaccine
Description: Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.
Study NCT00112957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rF-NY-ESO-1 vaccine
Description: Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
Study NCT04677257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI, invasive coronary physiology and CMR
Description: Patients with acute STEMI will undergo invasive assessment of coronary physiology (IMR and CFR) following successful primary PCI and CMR within a week of the acute event
Study NCT01807455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital Lidocaine
Study NCT04057768 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
Study NCT02935387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taper
Description: Taper
Study NCT02935387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taper
Description: Taper
Study NCT02646163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2055
Description: (First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks.
Study NCT00149643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
Study NCT00149643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
Study NCT02412943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Description: Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
Study NCT02313155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TAK-850
Description: TAK-850 0.5 mL, Subcutaneous injection
Study NCT02313155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of TAK-850
Description: TAK-850 0.5 mL, Intramuscular injection
Study NCT00689936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and low-dose dexamethasone
Description: Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
Study NCT00777543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: wholegrain bread
Description: The control is the wholegrain bread enriched with bran that has not been pretreated
Study NCT03960528 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
Study NCT03960528 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
Study NCT03323749 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
Study NCT03323749 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
Study NCT03323749 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: elamipretide open label treatment
Description: 40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system